AVDL

Insider Trades

Name	Value	Action	Price	Current Price
Weiss Asset Management LPOther: Former 10% Owner $233M11.1M shares SellFeb 13, 2026 $21.00 $21.64

News

seekingalpha.comAlkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorextonseekingalpha.comJun 19

Trade AVDL

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials. This therapeutic candidate aims to alleviate severe daytime somnolence and sudden muscle weakness (cataplexy) in adult individuals afflicted with narcolepsy. Established in 2015, the entity was formerly recognized as Flamel Technologies SA before rebranding as Avadel Pharmaceuticals plc in January 2017. Its global headquarters are situated in Dublin, Ireland.

CEO: Gregory J. Divis Jr.
IPO Date: Jun 7, 1996

Market Data

Open: $21.64
High: $21.64
Low: $21.64
Volume: 35M
52W High: $23.57
52W Low: $6.38

Valuation

Market Cap: $2.1B
Enterprise Value: $2.1B

Financials

Free Cash Flow: -$46.9M
Revenue: $169.1M
Net Income: -$48.8M
Cash: $51.4M
Debt: $1.7M

Events

EarningsMar 2

EPS est. 0.08 · actual -0.05